Literature DB >> 11809190

Interpretation of the international normalised ratio in patients with liver disease.

Steven R Deitcher.   

Abstract

Wide acceptance of the international normalised ratio (INR) and thromboplastins with low international sensitivity indices (ISIs) has inadvertently led to the application of the INR to patients other than those on anticoagulation treatment. I examined the degree of factor deficiency for a given INR in patients with liver disease and controls receiving stable-dose warfarin. The degree of factor V and VII, but not prothrombin, deficiencies for a given INR were greater in liver patients than controls. The INR measured with a low-ISI thromboplastin can quantify the coagulation status of patients with liver disease, but should not be interpreted as having the same meaning as the INR in patients receiving warfarin.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11809190     DOI： 10.1016/S0140-6736(02)07282-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Proteomic analyses of human plasma: Venus versus Mars.

Authors:  Christopher C Silliman; Monika Dzieciatkowska; Ernest E Moore; Marguerite R Kelher; Anirban Banerjee; Xiayuan Liang; Kevin J Land; Kirk C Hansen
Journal:  Transfusion       Date:  2011-08-31       Impact factor: 3.157

3.  Clinical usefulness of international normalized ratio calibration of prothrombin time in patients with chronic liver disease.

Authors:  Jun Hyung Lee; Oh Joo Kweon; Mi-Kyung Lee; Hyun Woong Lee; Hyung Joon Kim; Hye Ryoun Kim
Journal:  Int J Hematol       Date:  2015-06-12       Impact factor: 2.490

4.  Deep Venous Thrombosis and Pulmonary Embolism.

Authors:  Steven R. Deitcher; Teresa L. Carman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-06

5.  Management of Pulmonary Embolism: 2010 State-of-the-Art Update.

Authors:  Teresa L Carman; Florian Gegaj
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-04

6.  No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Authors:  Karin Wåhlander; Maria Eriksson-Lepkowska; Lars Frison; Gunnar Fager; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Venous thromboembolism in cirrhosis.

Authors:  Zhineng J Yang; Karen A Costa; Enrico M Novelli; Roy E Smith
Journal:  Clin Appl Thromb Hemost       Date:  2012-10-17       Impact factor: 2.389

8.  Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt.

Authors:  B Angermayr; M Cejna; F Karnel; M Gschwantler; F Koenig; J Pidlich; H Mendel; L Pichler; M Wichlas; A Kreil; M Schmid; A Ferlitsch; E Lipinski; H Brunner; J Lammer; P Ferenci; A Gangl; M Peck-Radosavljevic
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

9.  Prophylactic plasma transfusion for patients undergoing non-cardiac surgery.

Authors:  Jonathan Huber; Simon J Stanworth; Carolyn Doree; Marialena Trivella; Susan J Brunskill; Sally Hopewell; Kirstin L Wilkinson; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2017-08-17

10.  Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.

Authors:  Camilo Molino Guidoni; Paulo Roque Obreli-Neto; Leonardo Regis Leira Pereira
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.